1. Home
  2. TFSL vs RARE Comparison

TFSL vs RARE Comparison

Compare TFSL & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TFSL
  • RARE
  • Stock Information
  • Founded
  • TFSL 1938
  • RARE 2010
  • Country
  • TFSL United States
  • RARE United States
  • Employees
  • TFSL N/A
  • RARE N/A
  • Industry
  • TFSL Savings Institutions
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • TFSL Finance
  • RARE Health Care
  • Exchange
  • TFSL Nasdaq
  • RARE Nasdaq
  • Market Cap
  • TFSL 3.6B
  • RARE 2.6B
  • IPO Year
  • TFSL 2007
  • RARE 2014
  • Fundamental
  • Price
  • TFSL $12.61
  • RARE $27.14
  • Analyst Decision
  • TFSL Hold
  • RARE Strong Buy
  • Analyst Count
  • TFSL 1
  • RARE 16
  • Target Price
  • TFSL $15.00
  • RARE $86.94
  • AVG Volume (30 Days)
  • TFSL 287.8K
  • RARE 3.2M
  • Earning Date
  • TFSL 08-12-2025
  • RARE 08-05-2025
  • Dividend Yield
  • TFSL 8.90%
  • RARE N/A
  • EPS Growth
  • TFSL 0.98
  • RARE N/A
  • EPS
  • TFSL 0.28
  • RARE N/A
  • Revenue
  • TFSL $304,101,000.00
  • RARE $590,689,000.00
  • Revenue This Year
  • TFSL $6.24
  • RARE $18.70
  • Revenue Next Year
  • TFSL $3.83
  • RARE $26.76
  • P/E Ratio
  • TFSL $45.34
  • RARE N/A
  • Revenue Growth
  • TFSL 0.00
  • RARE 33.46
  • 52 Week Low
  • TFSL $11.29
  • RARE $25.81
  • 52 Week High
  • TFSL $15.00
  • RARE $60.37
  • Technical
  • Relative Strength Index (RSI)
  • TFSL 36.49
  • RARE 33.02
  • Support Level
  • TFSL $12.62
  • RARE $27.00
  • Resistance Level
  • TFSL $13.18
  • RARE $28.48
  • Average True Range (ATR)
  • TFSL 0.20
  • RARE 1.33
  • MACD
  • TFSL -0.05
  • RARE -0.05
  • Stochastic Oscillator
  • TFSL 6.35
  • RARE 26.23

About TFSL TFS Financial Corporation

TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: